Skip to content

CancerIndexthe global index of cancer

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Pulse Data updates Year in cancer Taxonomy Countries Compare Trial intelligence Trial map Drug pipeline Sources Methodology About Trust & policies Data downloads Developers (API)

Loading cancer entity…

CancerIndex

CancerIndex is a research and information platform. It is not a physician, does not diagnose, and does not recommend treatment. Population statistics do not predict individual outcomes.

Every number links to its source and retrieval date. Derived metrics carry a formula version. AI-generated synthesis is not enabled in this phase; all content is database-grounded.

About Trust & policies Data explorer Data downloads Pulse Data update log Developers (API)Sources Methodology Taxonomy Countries Compare Contact · contact@spboucher.ai Status

© 2026 CancerIndex · built and maintained by Simon-Pierre Boucher · contact contact@spboucher.ai · hosted on MacLustr (www.maclustr.io). Source data remains under the license of each provider — see /sources.

Melanocytic Neoplasm — Research · CancerIndex

Cancers
Neoplasm
Neoplasm by Morphology
Melanocytic Neoplasm

Cancer Family

Melanocytic Neoplasm

CI-CAN-00000026Explore in graph →

Non-malignant609 active trials13 approved drugs233 evidence items

NCIt: C7058

Overview
Statistics
Survival
Genomics26
Variants & evidence233
Drugs64
Trials3258
Research
Rankings
Sources & provenance

Research activity

PubMed record counts

Each count is the number of PubMed records returned by the exact query shown, at the time it was run. Counts are research-activity signals, not quality measures.

Data not yet available

No PubMed query has been run for this entity. Counts require a MeSH-anchored query built from the entity's terminology mappings; the query string is stored with each count so it can be reproduced.

What CancerIndex knows

Trials tab
Methodology: publication counts

Literature

Linked publications (185)

Publications linked to this entity or its descendants, newest first, 25 per page. Link method and validation status are shown; 'candidate' links have not been reviewed.

pubmedProvenance

Source: PubMed (NLM)
Dataset: PubMed E-utilities
Retrieved: Sep 8, 2026
Layer: normalized (units and labels harmonized; values unchanged)

PublishedShowing 101–125 of 185 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

Increased MAPK reactivation in early resistance to dabrafenib/trametinib combination therapy of BRAF-mutant metastatic melanoma.
· Nat Commun · 2014 · PMID 25452114 · validated civic_curation pubmed
Significant Clinical Response to a MEK Inhibitor Therapy in a Patient With Metastatic Melanoma Harboring an RAF1 Fusion.
· JCO Precis Oncol · 2018 · PMID 35135096 · validated civic_curation pubmed
Major response to imatinib mesylate in KIT-mutated melanoma.
· J Clin Oncol · 2008 · PMID 18421059 · validated civic_curation pubmed
Sunitinib therapy for melanoma patients with KIT mutations.
· Clin Cancer Res · 2012 · PMID 22261812 · validated civic_curation pubmed
Long Term Survival and Continued Complete Response of Vemurafenib in a Metastatic Melanoma Patient with BRAF V600K Mutation.
· Case Rep Oncol Med · 2016 · PMID 26989536 · validated civic_curation pubmed
BRAF(L597) mutations in melanoma are associated with sensitivity to MEK inhibitors.
· Cancer Discov · 2012 · PMID 22798288 · validated civic_curation pubmed
The distribution of BRAF gene fusions in solid tumors and response to targeted therapy.
· Int J Cancer · 2016 · PMID 26314551 · validated civic_curation pubmed

Showing 101–125 of 185 publications

← Previous
1
…
4
5
6
7
8
Next →

KIT as a therapeutic target in metastatic melanoma.

· JAMA · 2011 · PMID 21642685 · validated civic_curation pubmed

Activity of trametinib in K601E and L597Q BRAF mutation-positive metastatic melanoma.

· Melanoma Res · 2014 · PMID 24933606 · validated civic_curation pubmed

Characterization of S628N: a novel KIT mutation found in a metastatic melanoma.

· JAMA Dermatol · 2014 · PMID 25317746 · validated civic_curation pubmed

CDKN2A germline splicing mutation affecting both p16(ink4) and p14(arf) RNA processing in a melanoma/neurofibroma kindred.

· Genes Chromosomes Cancer · 2001 · PMID 11433531 · validated civic_curation pubmed

Kinase fusions are frequent in Spitz tumours and spitzoid melanomas.

· Nat Commun · 2014 · PMID 24445538 · validated civic_curation pubmed

Targeting RAF1 gene fusions with MEK inhibition in metastatic melanoma.

· Oncologist · 2025 · PMID 39504576 · validated civic_curation pubmed

Exploring Molecular Genetic Alterations and RAF Fusions in Melanoma: A Belvarafenib Expanded Access Program in Patients with RAS/RAF-Mutant Melanoma.

· Oncologist · 2024 · PMID 38470950 · validated civic_curation pubmed

BRAF and NRAS mutations in melanoma: potential relationships to clinical response to HSP90 inhibitors.

· Mol Cancer Ther · 2008 · PMID 18375819 · validated civic_curation pubmed

NRAS-mutant melanoma: response to chemotherapy.

· Arch Dermatol · 2011 · PMID 21576590 · validated civic_curation pubmed

Recurrent BRAF kinase fusions in melanocytic tumors offer an opportunity for targeted therapy.

· Pigment Cell Melanoma Res · 2013 · PMID 23890088 · validated civic_curation pubmed

First-in-human phase I study of pictilisib (GDC-0941), a potent pan-class I phosphatidylinositol-3-kinase (PI3K) inhibitor, in patients with advanced solid tumors.

· Clin Cancer Res · 2015 · PMID 25370471 · validated civic_curation pubmed

Multicenter phase I trial of the mitogen-activated protein kinase 1/2 inhibitor BAY 86-9766 in patients with advanced cancer.

· Clin Cancer Res · 2013 · PMID 23434733 · validated civic_curation pubmed

Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers.

· J Clin Oncol · 2008 · PMID 18390968 · validated civic_curation pubmed

Whole-genome sequencing reveals complex mechanisms of intrinsic resistance to BRAF inhibition.

· Ann Oncol · 2014 · PMID 24504448 · validated civic_curation pubmed

Clinical activity of the MEK inhibitor trametinib in metastatic melanoma containing BRAF kinase fusion.

· Pigment Cell Melanoma Res · 2015 · PMID 26072686 · validated civic_curation pubmed

Dose-dependent, complete response to imatinib of a metastatic mucosal melanoma with a K642E KIT mutation.

· Pigment Cell Melanoma Res · 2008 · PMID 18510589 · validated civic_curation pubmed

A novel DPP10 (intergenic)-NTRK3 fusion in a patient with facial malignant melanoma and potentially benefit from NTRK inhibitors.

· Oral Oncol · 2021 · PMID 33846089 · validated civic_curation pubmed

Overwhelming response to Dabrafenib in a patient with double BRAF mutation (V600E; V600M) metastatic malignant melanoma.

· J Hematol Oncol · 2012 · PMID 23031422 · validated civic_curation pubmed